FibroBiologics Inc. (FBLG)
FibroBiologics Inc. (FBLG) Stock Price, Analysis & Data
| Bid | 1 |
| Market Cap | 7.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.14M |
| Beta | 1.22 |
| EPS (ttm) | -5.47 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.34 |
| P/B (ttm) | 1.46 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 14, 2025 |
| Ask | 1.03 |
| Volume | 294,932 |
| Avg. Volume (20D) | 147,091 |
| Open | 1.00 |
| Previous Close | 1.03 |
| Day's Range | 0.98 - 1.15 |
| 52-Week Range | 0.62 - 12.80 |
| Analyst | Buy |
| Price Target | 12.5 (1026.13%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FBLG
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease;...
Financial Performance
In 2025, FibroBiologics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -18.65M, an increase of 67.06%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for FBLG stock is "Buy". The 12-month stock price forecast is 12.5, which is upside of 1026.13% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
